Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16,651 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I study of camrelizumab in patients with advanced solid tumors.
Ma Y, Cao J, Zhang Y, Liu Q, Fang W, Yang Y, Zhao Y, Yang Q, Zhao H, Zhang L. Ma Y, et al. Among authors: cao j. Signal Transduct Target Ther. 2023 Feb 1;8(1):47. doi: 10.1038/s41392-022-01213-6. Signal Transduct Target Ther. 2023. PMID: 36725836 Free PMC article. Clinical Trial. No abstract available.
Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.
Luo F, Lu FT, Qiu MZ, Zhou T, Ma WJ, Luo M, Zeng KM, Luo QY, Pan WT, Zhang L, Xia ZF, Zhang ZH, Cao JX, Zhao HY, Zhang L, Yang DJ. Luo F, et al. Cell Death Dis. 2021 Aug 5;12(8):772. doi: 10.1038/s41419-021-04042-7. Cell Death Dis. 2021. PMID: 34354046 Free PMC article.
Predictive value of a reduction in the level of high-density lipoprotein-cholesterol in patients with non-small-cell lung cancer undergoing radical resection and adjuvant chemotherapy: a retrospective observational study.
Luo F, Zeng KM, Cao JX, Zhou T, Lin SX, Ma WJ, Yang YP, Zhang ZH, Lu FT, Huang Y, Zhao HY, Zhang L. Luo F, et al. Lipids Health Dis. 2021 Sep 20;20(1):109. doi: 10.1186/s12944-021-01538-1. Lipids Health Dis. 2021. PMID: 34544437 Free PMC article.
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation.
Luo F, Li H, Ma W, Cao J, Chen Q, Lu F, Qiu M, Zhou P, Xia Z, Zeng K, Zhan J, Zhou T, Luo Q, Pan W, Zhang L, Lin C, Huang Y, Zhang L, Yang D, Zhao H. Luo F, et al. Among authors: cao j. Cell Mol Immunol. 2024 Jan;21(1):60-79. doi: 10.1038/s41423-023-01112-y. Epub 2023 Dec 7. Cell Mol Immunol. 2024. PMID: 38062129 Free PMC article.
16,651 results
You have reached the last available page of results. Please see the User Guide for more information.